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PRELIMINARY RESULTS OF A U.S.-BASED
STUDY TO VALIDATE THE ACUTE BRONCHITIS
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OBJECTIVE: To evaluate the psychometric characteris-
tics of the Acute Bronchitis Symptom Severity Scale
(ABSS).
METHODS: The ABSS is a seven-question, bronchitis
speciﬁc, instrument. Responses are measured on a scale
of 0–4. The total score is calculated as the mean of the
seven responses with higher scores indicating greater dis-
tress. The ABSS was pilot tested as a part of a US-based
prospective, naturalistic study to patients with acute exac-
erbation of chronic bronchitis at the pre-treatment visit,
each day of the ﬁrst ﬁve days of therapy with any anti-
microbial agent, and at the test-of-cure visit (TOC, 18–21
days post therapy). Item and total scale performance,
internal consistency (Cronbach’s alpha), construct valid-
ity (correlation with St. George’s Respiratory Question-
naire or SGRQ subscale), and responsiveness to change
over time (based on clinician evaluation and patient’s 
perceived treatment efﬁcacy) were examined.
RESULTS: Twenty-seven patients were enrolled at four
study sites in the US. Mean age was 57.4 (+14.5) years;
74% were female. No ﬂoor or ceiling effects were seen.
Consistent with an improvement in acute bronchitis
symptoms over time, mean item and total score values
declined from baseline to TOC. Cronbach’s alpha at each
time point ranged from 0.70 to 0.88, exceeding the reli-
ability guideline of 0.70 for a new measure. At TOC, the
correlation between the ABSS total score and SGRQ
activity subscale score was strong (0.60). The 18 patients
considered clinically cured or improved at day 5 reported
a mean ABSS score change, from baseline, of -0.90.
Patients who considered the treatment moderately effec-
tive at day 5 (n = 11) reported an average change score
of -0.87, while those who considered the treatment very
effective (n = 3) improved by a score of -1.50.
CONCLUSIONS: Preliminary results from this pilot test
with US-based patients suggest the instrument is valid,
reliable, and sensitive to change over time.
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THE ASSOCIATION BETWEEN HEALTH
RELATED QUALITY OF LIFE AND ADHERENCE
TO THERAPY IN HEPATITIS C
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For many conditions the overall impact of treatment on
health related quality of life (HRQL) involves a tradeoff
between improvement in the condition being treated and
unwanted side effects. When the net HRQL result is too
negative, patients have difﬁculty tolerating medication
and may fail to adhere or discontinue treatment.
OBJECTIVE: We investigated the association between
reduced HRQL due to interferon treatment and prema-
ture treatment discontinuation for chronic hepatitis C.
METHODS: A pooled secondary analysis of patients (n
= 1441) across three international, multicenter, open-
label, randomized studies that compared peginterferon 
a-2a with interferon a-2a. Health-related quality of life
was assessed using the SF-36 Health Survey. The Fatigue
Severity Scale (FSS) was used to measure the impact of
disabling fatigue. Logistic regression analysis was used 
to examine the association between changes in health-
related quality of life and treatment discontinuation.
RESULTS: Reduction from baseline in HRQL scores was
a signiﬁcant predictor of in-treatment SF-36 scores 
(P < 0.001). The odds of discontinuing treatment early
were 48% higher in the quartile of patients with the great-
est worsening of fatigue scores than in the lowest quar-
tile. The odds ratios for treatment discontinuation among
patients with worsening of SF-36 domain and summary
scores ranged from 1.09 (physical function) to 3.56 (role
limitations-emotional). 
CONCLUSION: The impact on health-related quality of
life is an important consideration in optimizing treatment
of patients with chronic hepatitis C. HRQL assessments
during treatment may offer physicians a method for 
monitoring the risk of premature discontinuation.
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OBJECTIVE: To build a utility-based model comparing
physicians’ prescribing practices for acute sinusitis,
assuming that utility is a function of repeat visits, second
prescriptions and call-backs.
METHODS: An algorithm is applied to data from an
open-label, multicenter, randomized trial, which docu-
ments call back times, ofﬁce visits and second prescrip-
tions for 792 Acute Bacterial Sinusitis patients treated
with Amoxicillin clavulanate 875mg, Levoﬂoxacin 
500mg or Moxiﬂoxacin 400mg. The marginal effect of
fewer call-backs, ofﬁce visits and second prescriptions,
using utility as a function of these, is represented by a
decision tree. Probabilities from the trial are used. Utili-
ties range from highest (1.00) when the patient does not
call back or get a second prescription, to lowest (0.25),
when the patient calls back/comes back for a visit. Inter-
mediate utilities range in decreasing order from call-
back/no action, to no call-back/second prescription, to
